Cardiac Magnetic Resonance guidance of Implantable Cardioverter Defibrillator implantation in non-ischaemic dilated cardiomyopathy (CMR-ICD-DZHK23)

ID

NCT04558723

Status

Active

DZG

DZHK

Start date

01/14/2021

Parameters

Inclusion criteria
  • NIDCM (idiopathic or familial)* LVEF ≤35% and presence of fibrosis on CMR Diagnostic CMR scan Age ≥18 years Written informed consent Ability to give informed consent
Exclusion criteria
  • ICM [previous myocardial infarction
  • previous percutaneous coronary intervention] Other cardiomyopathies (hypertrophic cardiomyopathy
  • arrhythmogenic right ventricular cardiomyopathy
  • restrictive cardiomyopathy
  • infiltrative cardiomyopathies [e.g. cardiac amyloidosis
  • cardiac sarcoidosis
  • hemochromatosis and iron overload cardiomyopathy]
  • left ventricular non-compaction cardiomyopathy
  • reversible cardiomyopathies [Takotsubo syndrrome
  • peripartum cardiomyopathy
  • chemotherapy induced cardiomyopathy]. Myocarditis Contraindication for CMR at study entry (including severe claustrophobia
  • pacemaker or ICD
  • metallic cerebral or intracranial implants
  • known allergy to gadolinium) Severe renal insufficiency (creatinine clearance <30 mL/min) Current pacemaker or defibrillator in situ Current indication for device therapy (e.g. secondary prophylaxis after aborted SCD) Renal impairment defined as an eGFR <30 milliliters Age <18 years Patients presenting with pregnancy Patients without informed consent Participation in another randomized trial Life expectancy <2 years